Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation-inducing agents

Wei Zhang, Mieczyslaw A. Piatyszek, Tohru Kobayashi, Elihu Estey, Michael Andreeff, Albert B. Deisseroth, Woodring E. Wright, Jerry W. Shay

Research output: Contribution to journalArticle

117 Citations (Scopus)

Abstract

The terminal regions of human chromosomes, the telomeres, shorten with each cell division in most normal somatic cells. Telomerase, a ribonucleoprotein that synthesizes telomeric DNA onto chromosomal ends, is activated in germline cells and almost all tumor cells. Telomerase activity maintains the stability of telomere length, resulting in indefinite cellular proliferation (immortality). In the present study, telomerase activity was analyzed in leukemic mononuclear blood cells obtained from 56 patients with acute myelogenous leukemia (AML) with known cytogenetic alterations. Heterogenous levels of telomerase activity were observed and generally correlated with cytogenetic status. Patients with 11q abnormalities and -5/-7 (unfavorable cytogenetics) tended to have high telomerase activity compared with cells obtained from AML patients with other types of cytogenetics. Additional studies with a larger cohort of patients will determine whether these differences are statistically significant. Chemotherapy agents that result in differentiation of leukemic cells also resulted in inhibition of telomerase activity. Knowledge of telomerase activity in patients with AML, before and throughout therapy, may have clinical utility for following disease progression and may predict early cancer relapse.

Original languageEnglish (US)
Pages (from-to)799-803
Number of pages5
JournalClinical Cancer Research
Volume2
Issue number5
StatePublished - May 1996

Fingerprint

Telomerase
Acute Myeloid Leukemia
Human Activities
Cytogenetics
Telomere Shortening
Ribonucleoproteins
Telomere
Human Chromosomes
Cell Division
Disease Progression
Cell Differentiation
Blood Cells
Neoplasms
Cell Proliferation
Recurrence
Drug Therapy
DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Zhang, W., Piatyszek, M. A., Kobayashi, T., Estey, E., Andreeff, M., Deisseroth, A. B., ... Shay, J. W. (1996). Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation-inducing agents. Clinical Cancer Research, 2(5), 799-803.

Telomerase activity in human acute myelogenous leukemia : Inhibition of telomerase activity by differentiation-inducing agents. / Zhang, Wei; Piatyszek, Mieczyslaw A.; Kobayashi, Tohru; Estey, Elihu; Andreeff, Michael; Deisseroth, Albert B.; Wright, Woodring E.; Shay, Jerry W.

In: Clinical Cancer Research, Vol. 2, No. 5, 05.1996, p. 799-803.

Research output: Contribution to journalArticle

Zhang, W, Piatyszek, MA, Kobayashi, T, Estey, E, Andreeff, M, Deisseroth, AB, Wright, WE & Shay, JW 1996, 'Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation-inducing agents', Clinical Cancer Research, vol. 2, no. 5, pp. 799-803.
Zhang W, Piatyszek MA, Kobayashi T, Estey E, Andreeff M, Deisseroth AB et al. Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation-inducing agents. Clinical Cancer Research. 1996 May;2(5):799-803.
Zhang, Wei ; Piatyszek, Mieczyslaw A. ; Kobayashi, Tohru ; Estey, Elihu ; Andreeff, Michael ; Deisseroth, Albert B. ; Wright, Woodring E. ; Shay, Jerry W. / Telomerase activity in human acute myelogenous leukemia : Inhibition of telomerase activity by differentiation-inducing agents. In: Clinical Cancer Research. 1996 ; Vol. 2, No. 5. pp. 799-803.
@article{73cfe56c2d8b4cd397c1df9ebf65b542,
title = "Telomerase activity in human acute myelogenous leukemia: Inhibition of telomerase activity by differentiation-inducing agents",
abstract = "The terminal regions of human chromosomes, the telomeres, shorten with each cell division in most normal somatic cells. Telomerase, a ribonucleoprotein that synthesizes telomeric DNA onto chromosomal ends, is activated in germline cells and almost all tumor cells. Telomerase activity maintains the stability of telomere length, resulting in indefinite cellular proliferation (immortality). In the present study, telomerase activity was analyzed in leukemic mononuclear blood cells obtained from 56 patients with acute myelogenous leukemia (AML) with known cytogenetic alterations. Heterogenous levels of telomerase activity were observed and generally correlated with cytogenetic status. Patients with 11q abnormalities and -5/-7 (unfavorable cytogenetics) tended to have high telomerase activity compared with cells obtained from AML patients with other types of cytogenetics. Additional studies with a larger cohort of patients will determine whether these differences are statistically significant. Chemotherapy agents that result in differentiation of leukemic cells also resulted in inhibition of telomerase activity. Knowledge of telomerase activity in patients with AML, before and throughout therapy, may have clinical utility for following disease progression and may predict early cancer relapse.",
author = "Wei Zhang and Piatyszek, {Mieczyslaw A.} and Tohru Kobayashi and Elihu Estey and Michael Andreeff and Deisseroth, {Albert B.} and Wright, {Woodring E.} and Shay, {Jerry W.}",
year = "1996",
month = "5",
language = "English (US)",
volume = "2",
pages = "799--803",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Telomerase activity in human acute myelogenous leukemia

T2 - Inhibition of telomerase activity by differentiation-inducing agents

AU - Zhang, Wei

AU - Piatyszek, Mieczyslaw A.

AU - Kobayashi, Tohru

AU - Estey, Elihu

AU - Andreeff, Michael

AU - Deisseroth, Albert B.

AU - Wright, Woodring E.

AU - Shay, Jerry W.

PY - 1996/5

Y1 - 1996/5

N2 - The terminal regions of human chromosomes, the telomeres, shorten with each cell division in most normal somatic cells. Telomerase, a ribonucleoprotein that synthesizes telomeric DNA onto chromosomal ends, is activated in germline cells and almost all tumor cells. Telomerase activity maintains the stability of telomere length, resulting in indefinite cellular proliferation (immortality). In the present study, telomerase activity was analyzed in leukemic mononuclear blood cells obtained from 56 patients with acute myelogenous leukemia (AML) with known cytogenetic alterations. Heterogenous levels of telomerase activity were observed and generally correlated with cytogenetic status. Patients with 11q abnormalities and -5/-7 (unfavorable cytogenetics) tended to have high telomerase activity compared with cells obtained from AML patients with other types of cytogenetics. Additional studies with a larger cohort of patients will determine whether these differences are statistically significant. Chemotherapy agents that result in differentiation of leukemic cells also resulted in inhibition of telomerase activity. Knowledge of telomerase activity in patients with AML, before and throughout therapy, may have clinical utility for following disease progression and may predict early cancer relapse.

AB - The terminal regions of human chromosomes, the telomeres, shorten with each cell division in most normal somatic cells. Telomerase, a ribonucleoprotein that synthesizes telomeric DNA onto chromosomal ends, is activated in germline cells and almost all tumor cells. Telomerase activity maintains the stability of telomere length, resulting in indefinite cellular proliferation (immortality). In the present study, telomerase activity was analyzed in leukemic mononuclear blood cells obtained from 56 patients with acute myelogenous leukemia (AML) with known cytogenetic alterations. Heterogenous levels of telomerase activity were observed and generally correlated with cytogenetic status. Patients with 11q abnormalities and -5/-7 (unfavorable cytogenetics) tended to have high telomerase activity compared with cells obtained from AML patients with other types of cytogenetics. Additional studies with a larger cohort of patients will determine whether these differences are statistically significant. Chemotherapy agents that result in differentiation of leukemic cells also resulted in inhibition of telomerase activity. Knowledge of telomerase activity in patients with AML, before and throughout therapy, may have clinical utility for following disease progression and may predict early cancer relapse.

UR - http://www.scopus.com/inward/record.url?scp=0029953160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029953160&partnerID=8YFLogxK

M3 - Article

C2 - 9816233

AN - SCOPUS:0029953160

VL - 2

SP - 799

EP - 803

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -